Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 23928184)

1.

Symposium on prions and transfusion safety.

Coste J.

Transfus Clin Biol. 2013 Sep;20(4):393-4. doi: 10.1016/j.tracli.2013.05.001. Epub 2013 Aug 6. No abstract available.

PMID:
23928184
2.

Risk of transmission of Creutzfeldt-Jakob disease via blood and blood products. The French risk-analysis over the last 15 years.

Martin M, Trouvin JH.

Transfus Clin Biol. 2013 Sep;20(4):398-404. doi: 10.1016/j.tracli.2013.06.001. Epub 2013 Jul 30. Review.

PMID:
23910008
3.

The risk of transmission of nvCJD by blood transfusion and the potential benefits of leucodepletion.

Turner M.

Transfus Sci. 1998 Dec;19(4):331-2. No abstract available.

PMID:
10351147
4.

Variant Creutzfeldt-Jakob disease and prions in the blood supply.

Rohwer RG, Drohan W.

Clin Adv Hematol Oncol. 2004 Feb;2(2):84, 87, 131. No abstract available.

PMID:
16163166
5.

Blood-transmitted prions and variant Creutzfeldt-Jakob disease.

Grady GF, Vyas GN.

Biologicals. 2007 Apr;35(2):75-7. Epub 2007 Feb 20. No abstract available.

PMID:
17317213
6.

The safety of human blood: experimental TSE/prion infectivity studies.

Cervenakova L.

Transfus Clin Biol. 2001 Jun;8(3):260. No abstract available.

PMID:
11499973
7.

UK approach to assessing assays and filters designed to reduce the risk of transfusion-transmitted vCJD.

Thomas S, Turner ML, Williamson LM.

Transfus Clin Biol. 2013 Sep;20(4):405-11. doi: 10.1016/j.tracli.2013.05.002. Epub 2013 Aug 6.

PMID:
23928183
8.

Lessons from the response to the threat of transfusion-transmitted vCJD in Ireland.

Murphy WG.

Transfus Clin Biol. 2013 Sep;20(4):416-21. doi: 10.1016/j.tracli.2013.06.002. Epub 2013 Aug 31. Review.

PMID:
24001606
9.

Creutzfeldt-Jakob disease and the risk from blood or blood products.

Will RG, Kimberlin RH.

Vox Sang. 1998;75(3):178-80. Review.

PMID:
9852403
10.

Variant Creutzfeldt-Jakob disease (vCJD). Precautionary measures against the risk of transmission of the agent of vCJD by blood transfusion.

[No authors listed]

Wkly Epidemiol Rec. 2000 Nov 24;75(47):377-9. English, French. No abstract available.

PMID:
11144617
11.

Of mad cows and bolted horses: the economics of blood safety.

Murphy WG.

Transfusion. 2012 Nov;52(11):2278-81. doi: 10.1111/j.1537-2995.2012.03931.x. No abstract available.

PMID:
23140426
12.

NBA/NBS perspective on nvCJD.

Wallington T.

Transfus Sci. 1998 Dec;19(4):329-30. No abstract available.

PMID:
10351146
14.

Prion disease and blood transfusion.

Flanagan P, Barbara JA.

Transfus Med. 1996 Sep;6(3):213-5. No abstract available.

PMID:
8885149
15.

[Emergent viral threats in blood transfusion].

Pozzetto B, Garraud O.

Transfus Clin Biol. 2011 Apr;18(2):174-83. doi: 10.1016/j.tracli.2011.01.009. Epub 2011 Mar 16. Review. French.

PMID:
21414828
16.

Cost-effectiveness of prion filtration of red blood cells to reduce the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease in the Republic of Ireland.

Teljeur C, Flattery M, Harrington P, O'Neill M, Moran PS, Murphy L, Ryan M.

Transfusion. 2012 Nov;52(11):2285-93. doi: 10.1111/j.1537-2995.2012.03637.x. Epub 2012 Apr 9.

PMID:
22486387
17.

[Much news on the prion front].

Norrby E.

Lakartidningen. 2010 May 5-11;107(18):1218-24. Review. Swedish. No abstract available.

PMID:
20521593
18.

The spectrum of safety: variant Creutzfeldt-Jakob disease in the United Kingdom.

Ironside JW.

Semin Hematol. 2003 Jul;40(3 Suppl 3):16-22. Review.

PMID:
14690064
19.

[Unconventional transmissible agents: risk of transmission by blood].

Dormont D.

Transfus Clin Biol. 1998 Apr;5 Suppl 1:33S-35S. Review. French. No abstract available.

PMID:
9622843
20.

Removal of TSE agents from blood products.

Foster PR.

Vox Sang. 2004 Jul;87 Suppl 2:7-10. Review. No abstract available.

PMID:
15209867
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk